Besides, ERBB3, FGFR3, CTLA4, and LAG3 are also reported in some studies as potential therapeutic targets for bladder cancer (Tomlinson et al., 2007; Cancer Genome Atlas Research, 2014; Gofrit et al., 2014; Molyneaux et al., 2015; Vidotto et al., 2019). This evidence concerns the gene ERBB3 and urinary bladder cancer.